Effects of calcium antagonists in hypertensive patients with renal dysfunction: A prospective, randomized, parallel trial comparing benidipine and nifedipine

Nephrology

Volumn 9, Issue 5, 2004, Pages 265-271

  Inoue, Sanae ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benidipine; Blood pressure; Kidney; Nifedipine

Indexed keywords

BENIDIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; JAPAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; MALE; MIDDLE AGED; NIFEDIPINE; PROSPECTIVE STUDIES;

EID: 9644257190     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00272.x     Document Type: Article

References (42)

1. Fujishima M. Importance of hypertension treatment indicated by epidemiological data in Japan. Curr. Ther. 2003; 21: 8-13 (In Japanese).
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
3. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 1996; 334: 939-45.
4. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
5. Hebert LA, Kusek JW, Greene T et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30: 428-35.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851-60.
8. Parving H, Lehnert H, Bröcher-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-8.
9. Brenner BM, Cooper ME, Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-9.
10. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am. J. Kidney Dis. 2000; 36: 646-61.
11. Baba S, The J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diab. Res. Clin. Pract. 2001; 54: 191-201.
12. Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992; 42: 452-8.
13. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61: 1086-97.
14. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-72.
15. Noda H, Ito Y, Fujita T. The antihypertensive effect and pharmacokinetics after single oral administration of benidipine hydrochloride in patients with essential hypertension. Jpn Pharmacol. Ther. 1990; 18 (Suppl.): S703-11.
16. Shimada S, Nakajima Y, Yamamoto K, Sawada Y, Iga T. Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biol. Pharm. Bull. 1996; 19: 430-7.
17. Gotoh Y, Muraki K, Imaizumi Y, Watanabe M. Effects of benidipine, a 1, 4-dihydropyridine derivative, on single L-type Ca channel currents in vascular smooth muscle cells. Clin. Rep. 1992; 26: 3897-901.
18. Suzuki K, Imada T, Gao F, Ma H, Nagata T. Radioautographic study of benidipine hydrochloride. Arzneim.-Forsch./Drug Res. 1994; 44: 129-33.
19. Ishii A, Toyama J. Binding properties of (±) [3H] benidipine hydrochloride to rat heart membranes. J. Cardiovasc. Pharmacol. 1993; 21: 191-6.
20. Kimura K. Effects of benidipine hydrochloride on renal arterioles. Ther. Res. 1994; 15: 2237-340.
21. Kawata T, Hashimoto S, Takao K. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1997; 30: 431-6.
22. Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens. Res. 2002; 25: 571-6.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Lin J-L, Lin-Tan D-T, Hsu K-H, Yu C-C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N. Engl. J. Med. 2003; 348: 277-86.
25. Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch. Int. Med. 2003; 157: 2413-46.
26. WHO. 1999 World Health Organization-international society of hypertension guidelines for the management of hypertension. J. Hypertens. 1999; 17: 151-83.
27. Guidelines Subcommittee of the Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000). Tokyo: Japanese Society of Hypertension, 2000.
28. Staessen JA. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
29. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens. Res. 1996; 19 (Suppl. I): S1-8.
30. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573-9.
31. Hansson L, Zanchett A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
32. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285: 2719-28.
33. Nosaka C, Ishii A. Partition on [3H] benidipine hydrochloride into the lipid membrane. Clin. Rep. 1991; 25: 3887-93.
34. Yamada S, Nakajima M, Kusaka T, Uchida S, Kimura R. In vivo receptor binding of benidipine and amlodipine in mesenteric arteries and other tissues of spontaneously hypertensive rats. Life Sci. 2002; 70: 1999-2011.
35. Miyajima E, Kawano Y, Tochikubo O, Ishii M. Antihypertensive effect benidipine hydrochloride (coniel®) diurenal variations 24 h ambulatory blood pressure. Ther. Res. 1993; 14: 4055-62.
36. Miki S. Effect of benidipine hydrochloride, a Ca antagonist, on ambulatory blood pressure in patients with essential hypertension. Clin. Rep. 1993; 27: 4381-90.
37. Kakinoki S, Nomura A, Takechi S, Kitabatake A. Effects of short- and long-acting calcium channel blockers on the relationship between blood pressure and physical activity. Am. J. Hypertens. 2001; 14: 66-9.
38. Shike T, Tashiro K, Gohda T, Funabiki K, Shirato I, Tomino Y. Effect of calcium channel blockers, nifedipine and benidipine, on death of cultured mouse mesangial cells. Kidney Blood Press. Res. 2000; 23: 126-32.
39. Yao K, Sato H, Ina Y et al. Benidipine inhibits apoptosis during ischaemic acute renal failure in rats. J. Pharm. Pharmacol. 2000; 52: 561-8.
40. Das DK, Engelman RM, Maulik N. Oxygen free radical signaling in ischemic preconditioning. Ann. N. Y. Acad. Sci. 1999; 874: 49-65.
41. Shou I, Wang LN, Takahashi Y, Fukui M, Tomino Y. Effects of benidipine hydrochloride on antioxidant enzyme activity in stroke-prone spontaneous hypertensive rats (SHR-SP). J. Clin. Lab. Anal. 1997; 11: 158-62.
42. Yao K, Ina Y, Nagashima K, Ohmori K, Ohno T. Antioxidant effects of calcium antagonists in rat brain homogenates. Biol. Pharm. Bull. 2000; 23: 766-9.